The acquisition is expected to add more than $55 million in sales annually and be accretive to earnings in the first year.
Joseph Papa, chairman and CEO of Perrigo, said: “The acquisition of Galpharm further expands our global presence, complements our existing UK business and increases value for our shareholders. It also helps us meet the world’s growing need for quality, affordable healthcare.”